Catheter Precision Secures Tender From Leading Hospital in Hungary
FORT MILL, S.C., Dec. 03, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE American: VTAK), a leading U.S.-based medical device company focusing on advanced solutions in the cardiac electrophysiology market, is proud to announce that its VIVO™ system has successfully secured a significant tender at (Szeged University Hospital) in Hungary.
This achievement marks Catheter Precision’s inaugural installation in Hungary and reinforces its commitment to growth across Central and Eastern Europe. The tender was awarded in partnership with , a well-established local distributor. Installation of the VIVO system is anticipated in the first quarter of 2026.
Fatih Ayoglu, Sales Manager for EMEA & APAC, stated, “This multi-year award at Szeged University Hospital represents a pivotal milestone for Catheter Precision. It not only underscores the clinical value of the VIVO system but also emphasizes our strategic expansion into emerging markets. Hungary is a key region for us, and this installation paves the way for wider adoption throughout Central Europe.”
The VIVO system, engineered to offer non-invasive 3D localization of ventricular tachycardia prior to ablation, is increasingly recognized in premier hospitals across Europe. The award from Szeged University Hospital follows several recent multi-year agreements in France, further solidifying the system’s esteemed reputation among electrophysiology experts. This tender achievement embodies Catheter Precision’s ongoing mission to provide innovative technologies that enhance patient outcomes and expand its global footprint.
About VIVO™
Catheter Precision’s (View Into Ventricular Onset), is a non-invasive 3D imaging system that enables physicians to identify the origin of ventricular arrhythmias pre-procedure, thereby streamlining workflow and reducing procedure time. VIVO has received marketing clearance from the U.S. FDA and has the CE Mark.
About Catheter Precision
is an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias. It is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products.
Cautionary Note Regarding Forward-Looking Statements
Statements in this press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to substantial risk and uncertainties. Forward-looking statements can be identified by words such as “believe,” “anticipate,” “may,” “might,” “can,” “could,” “continue,” “depends,” “expect,” “expand,” “forecast,” “intend,” “predict,” “plan,” “rely,” “should,” “will,” “may,” “seek,” or the negative of these terms and other similar expressions, although not all forward-looking statements contain these words. These forward-looking statements include, but are not limited to, statements regarding product evaluations at the hospital, and that the purchase order indicates that the hospital and its staff see the value and benefits that VIVO can bring and expectations regarding VIVO evaluations in the coming weeks. The Company’s expectations and beliefs regarding these matters may not materialize. Actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of uncertainties, risks and changes in circumstances, including but not limited to risks and uncertainties included under the caption “Risk Factors” in the Company’s Form 10-K filed with the SEC and available at
The forward-looking statements included in this communication are made only as of the date hereof. The Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law.
CONTACTS:
Investor Relations
973-691-2000
# # #
